Cite
MLA Citation
Dean Harris et al.. “399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial.” Journal for immunotherapy of cancer, vol. 8, n.d., pp. A242–A243. http://access.bl.uk/ark:/81055/vdc_100144710526.0x000002